Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2025The Journal of ImmunologyOpen Access

Artificial Intelligence designed compound successfully inhibits TRPM7 enzyme domain 3623

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMax LechnerMFMarco FraticelliBHBirgit Hoeger

Discussion

Loading...

Member takes

Overview

Artificial intelligence identifies compound 11_F, which reduces TRPM7 kinase activity in Jurkat cells, implicating a novel treatment for GvHD.

Key Points

  • This research aims to identify and validate new inhibitors for the TRPM7 kinase, a target for GvHD treatment.
  • Used artificial intelligence to discover new small molecules targeting TRPM7 kinase.
  • Synthetically produced candidate compounds for testing.
  • Conducted radiometric in vitro screenings on Jurkat cells.
  • Identified compound 11_F as an effective TRPM7 kinase inhibitor with an IC50 of 30.5 µM.
  • Compound 11_F blocked phosphorylation of SMAD2, a TRPM7 kinase substrate.
  • The compound showed no toxicity in Jurkat cells.

Cite This Study

Lechner et al. (2025) studied this question.

synapsesocial.com/papers/69254f89c0ce034ddc359765https://doi.org/10.1093/jimmun/vkaf283.1401
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Exploring TRPM7 Channel-Kinase for Disease Modulation: A Translational Approach2026
  2. 2TRPM7 and magnesium orchestrate human CD4 T-cell activation and differentiation2025
  3. 3TRPM7 channel-kinase in immunity: new frontiers of an emerging therapeutic target2026 · 1 citations
  4. 4Pharmacological modulation of the TRPM7 channel using a natural product derivate 40432025
  5. 5Design, Synthesis and Biological Evaluation of New TRPM7 Channel Inhibitors as Potential Therapeutics for Breast Cancer2026